Breaking News

Theravance Discontinues JAK Inhibitor Program and Cuts 17% of Workforce

Strategic actions focus on commercialized and tangible assets rather than pipeline candidates and clinical trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Theravance Biopharma, based in Dublin and the Bay area, is discontinuing research activities for its inhaled Janus kinase (JAK) inhibitor program in lung inflammation and reducing its headcount by approximately 17% as part of an effort to sharpen the company’s focus and to create shareholder value.   These reductions are planned for completion by end of March 2023. Theravance plans to seek a partnership to continue progression of its inhaled JAK inhibitor program.   Strategic actions a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters